Back to today’s briefing

Story perspectives

Older Patients Thrive on Evolocumab, Yet Face Care Gap

2/6/2025

24 5

Summary

Story summary

Elderly patients over 75 with atherosclerotic cardiovascular disease experience remarkable benefits from the PCSK9 inhibitor evolocumab, achieving greater reductions in cardiovascular risk than their younger counterparts. Yet, a troubling treatment-risk paradox emerges as many older adults still lack access to optimal lipid-lowering therapy, underscoring a critical gap in care.

1 of 1

Story summary

Elderly patients over 75 with atherosclerotic cardiovascular disease experience remarkable benefits from the PCSK9 inhibitor evolocumab, achieving greater reductions in cardiovascular risk than their younger counterparts. Yet, a troubling treatment-risk paradox emerges as many older adults still lack access to optimal lipid-lowering therapy, underscoring a critical gap in care.